Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Injection use-powder ampoule for inhibiting thrombocyte agglutination and its preparation method

A technology for platelet aggregation and injection, which is applied in blood diseases, powder delivery, drug combination, etc., can solve the problems of insoluble particles and other problems, and achieve good stability, definite curative effect, and good stability

Active Publication Date: 2008-05-07
GRAND PHARM (CHINA) CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In our opinion, the use of citrate buffered injections for IV administration has the following disadvantages: Citrate buffer is still a relatively easy substance to generate insoluble particles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injection use-powder ampoule for inhibiting thrombocyte agglutination and its preparation method
  • Injection use-powder ampoule for inhibiting thrombocyte agglutination and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1 Prescription freeze-dried powder for injection of the present invention

[0012] Specification: 5mg / bottle (calculated as anhydrous tirofiban), the same below

[0013] Tirofiban Hydrochloride 5.618g

[0014] Mannitol 100g

[0015] Water for injection to 2000ml

[0016] A total of 1000 powder needles were made

[0017] Preparation Process:

[0018] Preparation of liquid medicine:

[0019] Take tirofiban hydrochloride and selected pharmaceutically acceptable carrier by prescription quantity, add in 1950ml water for injection, and add water to nearly full amount; After adding water for injection to the prescribed amount, measure the intermediate content and should be 93.0%~107.0%, After passing the test, filter it with a 0.45um microporous membrane, check the clarity and pass it, then pack it into controlled antibiotic bottles, and hand it over to the freeze-drying group.

[0020] Freeze-dried:

[0021] First cool down for 1 hour, the temperature drops ...

Embodiment 2

[0022] Embodiment 2 Prescription injection of the present invention aseptic subpackage powder injection

[0023] Tirofiban Hydrochloride 5.618g

[0024] Mannitol 100g

[0025] A total of 1000 powder needles were made

[0026] Preparation Process:

[0027] Weigh tirofiban hydrochloride and selected pharmaceutically acceptable carrier according to the prescription quantity, add in 300ml ethanol solution and dissolve, ethanol: water is 95:5, under sterile conditions, filter with 0.45um microporous membrane, check clarity After passing the test, dry it; the content of the inspection intermediate should be 93.0% to 107.0%, and after passing the ethanol residue, pack it into a controlled antibiotic bottle and press the composite aluminum cover.

Embodiment 3

[0028] Embodiment 3 contrasts with the injection containing citrate buffer

[0029] Tirofiban Hydrochloride 5.618g

[0030] Sodium chloride: 900g

[0031] Sodium citrate 54g

[0032] Citric acid 3.2g

[0033] A total of 1000 bottles of injection were made

[0034] Preparation Process:

[0035] Liquid preparation:

[0036] Weigh sodium chloride, citric acid and sodium citrate according to the prescription amount, add in 5000ml of newly prepared water for injection, stir until completely dissolved; weigh the active carbon of 0.3% solution amount, stir well, heat and boil for 15 minutes, after cooling, filter Remove activated carbon; accurately weigh tirofiban hydrochloride according to the prescription amount, completely dissolve it with water for injection, add it to the above sodium chloride solution, and add water for injection to nearly full amount; measure the pH at 5.5-6.5, add water for injection to the specified amount, Determination of intermediate content should ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A powder injection for suppressing the thrombocyte coagulation is proportionally prepared from tirofiban hydrochloride, the water for injection and the pharmacologically acceptable carrier chosen from lactose, mannitol, cane sugar, glucose, dextran, hydrolytic gelatin and sodium chloride through proportionally mixing, examining intermediate, adding water, filtering, loading in bottle and vacuum freeze drying.

Description

technical field [0001] The invention relates to a powder injection for inhibiting platelet aggregation and a preparation method thereof. Background technique [0002] Tirofiban hydrochloride (English name: Tirofiban hydrochloride, chemical name: (S)-N-(n-butylsulfonyl)-O-[4-(4-piperidinyl)butane]-L-tyrosine Hydrochloride monohydrate) is a salt compound of a platelet inhibitor. Tirofiban hydrochloride inhibits the binding of fibrinogen to platelets and inhibits platelet aggregation through the binding of fibrinogen receptor antagonists to glycoprotein (GP) IIb / IIIa fibrinogen receptor sites. The Chinese Patent Publication No. 1200676A of U.S. Mike Company has described the pharmaceutical composition of this compound, and this patent has described using citrate buffer to be superior to phosphate buffer, the citrate composition stability that contains tirofiban hydrochloride For more than 18 months, particles with a particle size greater than 50um can be seen in the solution ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/445A61K9/14A61P7/02
Inventor 耿海明钱自强杨波周建明
Owner GRAND PHARM (CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com